The evidence source should match the clinical question
Specialty utilization review often requires more than a general level-of-care criterion. Physician reviewers identify the applicable coverage framework first, then reconcile specialty guidance, drug information, regulatory labeling, and current clinical evidence with the individual patient’s diagnosis, prior treatment, biomarkers, comorbidities, risk, and requested service.
Coverage & Regulatory Requirements
Medicare NCDs/LCDs, applicable statutes and regulations, benefit requirements, health-plan medical policies, and other controlling coverage rules.
Authorized Clinical Criteria
Licensed or otherwise authorized decision-support criteria may inform severity, service intensity, level of care, and continued-stay analysis when applicable.
Specialty Guidance & Compendia
Recognized specialty guidelines and authoritative drug compendia help address disease-specific treatment, off-label therapy, sequencing, and uncommon indications.
Patient-Specific Physician Judgment
The final analysis integrates the documented clinical circumstances, treatment history, response, contraindications, alternatives, and risk.
Oncology and cancer-treatment review
Oncology UM may require review of cancer type, histology, stage, treatment intent, line of therapy, biomarker or molecular findings, prior treatment, performance status, organ function, dosing, and the applicable coverage policy. For Medicare off-label anticancer drug use, CMS recognizes specified authoritative compendia, including the NCCN Drugs & Biologics Compendium, Micromedex DrugDex, AHFS-DI, Clinical Pharmacology, and Lexi-Drugs, subject to applicable Medicare rules and support levels.
NCCN-based treatment context
NCCN disease guidance and the NCCN Drugs & Biologics Compendium can help evaluate regimen selection, sequencing, biomarker-directed therapy, and medically accepted off-label anticancer uses when applicable.
Uncommon or off-label indications
Recognized compendia such as Micromedex DrugDex and other CMS-recognized sources may be relevant when a requested anticancer use extends beyond FDA-approved labeling.
Medications, biologics, and unusual indications
Medication review may begin with the current FDA-approved Prescribing Information when the requested use is labeled. For off-label or uncommon indications, the reviewer may need to examine applicable coverage policy, recognized compendia where relevant, and qualifying peer-reviewed evidence. FDA labeling reflects the agency’s findings regarding safety and effectiveness under the labeled conditions of use; it does not by itself resolve every coverage question.
Approved labeling
Indication, population, route, dose, contraindications, warnings, and other labeled conditions of use may be material to medical-necessity review.
Peer-reviewed literature
High-quality published evidence may supplement specialty guidance or compendia when the clinical question is evolving or not fully resolved by a single source, subject to the applicable coverage framework.
Other specialty and procedural questions
Cardiology, neurology, infectious disease, gastroenterology, pulmonary medicine, rheumatology, surgery, devices, and other specialty reviews may require professional-society guidance, FDA device indications where relevant, Medicare coverage requirements, health-plan medical policy, and the supporting medical record.
Evidence-support tools
Clinical evidence platforms and literature-search tools can help physicians locate and synthesize current research. They are used as research support, not as substitutes for controlling Medicare requirements, FDA labeling, recognized compendia, payer medical policy, or primary-source evidence. Tools such as OpenEvidence may assist evidence retrieval when available and authorized within the review workflow.
Authoritative sources inform the review. They do not replace the patient.
The reviewer reconciles the applicable coverage requirements and evidence with the patient’s actual diagnosis, clinical trajectory, prior treatment, response, contraindications, alternatives, and documented risk.